Clal Biotech: How Much Of MediWound’s Value Is Really Accessible After The Share-Retention Rule And The Loan

What The Main Article Left Open

The main article already established that CBI’s discount is not just a book-to-market gap. It is a value-access problem: MediWound creates the value, but the parent cannot treat all of that value as if it were free cash. This follow-up isolates the most practical choke point in the story: how much of the MediWound stake is actually accessible to CBI while the Access loan remains outstanding and the company must keep at least one million MediWound shares.

The short answer is that the value exists, but it is sequenced. The full holding was worth about NIS 85.7 million at year-end 2025 and about NIS 75 million near the report date. But the loan cuts the parent’s freedom to act on the entire position at once. As long as the loan is still alive, only the slice above the one-million-share floor is the initial monetization room. That means the market does not need to give full credit for the entire NIS 75 million to NIS 85.7 million as if it were available now, but it is also too aggressive to read the setup as a dead end.

That is the key distinction: MediWound covers the debt mathematically, but it is not the same thing as cash sitting at the parent. For the value to become accessible, CBI first needs an orderly market transaction, then the loan has to be repaid, and only after that does the remaining stake become much freer.

The Value Bridge: How Many Shares Are Actually Free

CBI owns about 11.3% of MediWound. The MediWound financial statements attached to the annual report show 12,835,185 issued and outstanding shares at the end of 2025. Put those two figures together and the stake comes out to roughly 1.45 million shares. Against that, the loan terms require CBI to keep at least one million MediWound shares for as long as the debt remains unpaid.

That leaves only about 450 thousand shares as the first monetizable slice. This is roughly 31% of the position, not 100%, and not even half. That is exactly what the usual headline, that MediWound alone is worth more than CBI’s market cap, misses.

Once translated into value, the picture becomes much narrower:

Those numbers matter in two opposite ways. On one hand, they show that the constraint is real: the whole MediWound stake cannot be treated like an open cash box. On the other hand, they also show that the freely saleable slice alone is still larger than the loan. At year-end values, about $8.35 million of first-step monetization room stood against a loan of about $5.3 million. Even near the report date, after the holding value had fallen to about $24 million, the freely saleable slice was still worth about $7.45 million. So this is not a mathematical trap. It is an execution problem.

Why This Still Is Not Free Cash

This is where the layer the market is probably pricing comes in. CBI itself states that cash on hand is not enough to repay the debt, and that it may need to use financial transactions in its MediWound shares, including sales or debt refinancing, in order to meet the obligation. In the same risk discussion, the company also says that MediWound trading volume is sufficient, in its view, to allow share sales large enough to meet the debt on time, but it explicitly warns that a material change in the value of the holding or in trading volume could materially change that ability.

That is the real point. The question is not whether MediWound is worth more than the debt. It is. The question is whether that value can be turned into an actual financing event without damaging the escape route itself. A sharp drop in MediWound compresses the first monetizable layer. A decline in trading volume makes orderly execution harder. And while the loan remains outstanding, CBI also cannot take on new financing and cannot pledge assets to buy itself more time.

There is another reason this value is not the same as surplus cash. In 2025 the company sold about NIS 1.5 million of MediWound shares, and the proceeds were used to fund current operations. In the same year, operating cash flow was negative by about NIS 4 million, and year-end cash was only about NIS 1.6 million to NIS 1.7 million. So even if selling the free slice can clear the loan, it does not necessarily leave behind a clean equity cushion. Part of that money functions in practice as a parent-level liquidity bridge.

That means the intuitive calculation, NIS 75 million minus NIS 16.9 million of debt, is simply too aggressive for the near term. To get down to the one-million-share floor, the company first has to execute a sale. To make the retained one million shares stop functioning as part of the debt package, the company first has to clear the loan. And for what remains after that to feel like truly accessible value to common shareholders, the parent also has to stop burning cash at roughly the same pace.

Where Accessible Value Ends And Conditional Value Begins

This is exactly where the line sits between MediWound’s economic value and the value that is actually accessible to CBI shareholders.

The broad economic value is clear enough. Even after the holding value fell to about NIS 75 million near the report date, the MediWound stake alone was still larger than CBI’s market cap around the local market snapshot date, which stood at about NIS 50 million. This remains a very large asset relative to the listed parent wrapper.

But the near-term accessible value is much narrower. If the analysis stops at the first step, before the debt is repaid, the practical monetization room is only about NIS 23.3 million to NIS 26.6 million. If that is then offset by the year-end loan balance, what remains is about NIS 6.4 million to NIS 9.7 million, and that is before parent overhead, extra interest accruing after year-end, and transaction costs. That is already a very different number from the headline NIS 75 million to NIS 85.7 million.

At the same time, stopping there misses the second half of the story. If CBI can execute an orderly sale of the free slice and use it to clear the loan, the one-million-share retention rule falls away. In other words, the debt does not erase MediWound. It delays access to the rest of it. So the discount should not be read as a gap between a real asset and zero. It is a gap between value already created and value that still depends on a first monetization step, plus the market conditions that allow that step to happen.

That is also why liquidity in CBI’s own stock still matters even though it is not part of the direct MediWound bridge. A roughly NIS 50 million market cap and only about NIS 15.4 thousand of daily turnover leave the parent stock in a setup where even if the analytical math looks tempting, there is no fast market mechanism forcing the gap to close. The value may be there, but the path from asset value to listed-parent price remains slow, non-linear, and highly dependent on a financing event.

Bottom Line

This continuation does not change the thesis of the main article. It sharpens it. MediWound clearly carries more value than the books reflect, and that value also exceeds the debt. But as long as the Access loan remains alive, only about one-third of the position is free for a first sale. That translates into roughly NIS 23.3 million to NIS 26.6 million of immediate monetization room, not NIS 75 million to NIS 85.7 million of open cash.

That leads to two conclusions at once. First, the market does not have to give full credit for the entire MediWound value today. Second, if MediWound’s price and trading liquidity hold, CBI does have a real bridge to get through the debt and then make a much larger part of the holding accessible. So the key monitoring points are not just what MediWound is worth, but three much more practical questions: whether the parent can preserve enough cash until the first move, whether MediWound trading volumes remain adequate, and whether management chooses a direct sale, a refinancing, or a mix of the two before December 2026.